All In Biotech

Drug Trial Radar · NCT06151197

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

436

Actual

Start

Nov 28, 2023

Primary completion

Jun 9, 2026

Study completion Jun 9, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).

Conditions

  • Plantar Fibromatosis
  • Ledderhose Disease

Interventions

  • EN3835Biological

    Biologic: EN3835 injection

  • PlaceboOther

    Placebo injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)Time frame: Baseline, Week 12

Locations

66 sites in 2 countries. Site status is shown where the registry gives one.

  • Endo Site 42

    Mesa, Arizona

  • Endo Site 64

    Scottsdale, Arizona

  • Endo Site 11

    Tucson, Arizona

  • Endo Site 49

    Castro Valley, California

  • Endo Site 39

    Cerritos, California

  • Endo Site 31

    Corona, California

  • Endo Clinical Site 2

    Encinitas, California

  • Endo Site 8

    Fresno, California

  • Endo Site 28

    Lancaster, California

  • Endo Site 9

    Los Angeles, California

  • Endo Site 53

    Los Angeles, California

  • Endo Site 50

    San Francisco, California

  • Endo Site 29

    Sherman Oaks, California

  • Endo Site 30

    Tarzana, California

  • Endo Site 61

    Torrance, California

  • Endo Site 47

    Johnstown, Colorado

  • Endo Site 65

    Parker, Colorado

  • Endo Site 17

    Westminster, Colorado

  • Endo Site 22

    Hialeah, Florida

  • Endo Site 59

    Jacksonville, Florida

  • Endo Site 23

    Miami, Florida

  • Endo Site 26

    Miami, Florida

  • Endo Site 21

    Miami, Florida

  • Endo Site 35

    North Miami Beach, Florida

  • Endo Site 19

    Palm Beach Gardens, Florida

  • Endo Clinical Site 1

    Pinellas Park, Florida

  • Endo Site 14

    Plantation, Florida

  • Endo Site 60

    Sweetwater, Florida

  • Endo Site 33

    Virginia Gardens, Florida

  • Endo Site 24

    Lawrenceville, Georgia

  • Endo Site 27

    O'Fallon, Illinois

  • Endo Site 45

    Oak Brook, Illinois

  • Endo Site 54

    Overland Park, Kansas

  • Endo Site 56

    Shreveport, Louisiana

  • Endo Site 5

    Pasadena, Maryland

  • Endo Site 16

    Grand Rapids, Michigan

  • Endo Site 12

    Jefferson City, Missouri

  • Endo Site 51

    Billings, Montana

  • Endo Site 36

    Missoula, Montana

  • Endo Site 34

    Oradell, New Jersey

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.